ViroMed today announced the official launch of a joint cardiovascular study with the University of California, San Francisco. The purpose of this collaboration is to evaluate the efficacy of VM202 for the treatment of coronary artery disease, using cardiovascular magnetic resonance (CMR) imaging. The study will focus on the development of new magnetic resonance (MR) imaging that is expected to enable more accurate diagnosis and evaluation of the efficacy of the angiogenic therapeutics of VM202 - ViroMed’s leading therapeutic candidate product. Independently, the US phase I clinical trial for VM202 will begin at the Minneapolis Heart Institute in January 2007.
Dr. Maythem Saeed, Professor, Department of Radiology, School of Medicine, UCSF, received a contribution from Viromed to support his ongoing research on angiogenesis and gene therapy using cardiovascular magnetic resonance (CMR) imaging. Dr. Saeed stated "…that the development of the MRI-guided minimally invasive delivery system has proven to be effective in measuring the efficacy in gene therapeutics, such as VM202."
UCSF is a leading scientific research university that consistently defines health care worldwide by conducting advanced biomedical research, educating graduate students in the life sciences, and providing complex patient care.